What is CagriSema made of? CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. In REDEFINE 1, the combination produced greater average weight loss than either component alone at the studied regimens.
The useful question is what the same study found for each group. Comparing unrelated headline percentages cannot answer that as clearly.
What does each ingredient do?
- Cagrilintide: a long-acting analogue of amylin, a pancreatic hormone involved in feeling full. It is a different hormone pathway from GLP-1. See the original cagrilintide trial.
- Semaglutide: activates GLP-1 receptors. GLP-1 helps regulate appetite and calorie intake; semaglutide also affects glucose regulation and delays stomach emptying. See the Wegovy prescribing information, section 12.
- CagriSema: the combination studied by Novo Nordisk. Its two components are intended to act through these different pathways. That mechanism explains the research idea; the randomized trial tests the outcome.
What did the same trial find?
REDEFINE 1 randomly assigned 3,417 adults with overweight or obesity, without diabetes, to four groups for 68 weeks. All groups received a lifestyle intervention. It was a double-blind phase 3 trial funded by Novo Nordisk.
| Study group | Average loss |
|---|---|
| CagriSema | 20.4% |
| Semaglutide alone | 14.9% |
| Cagrilintide alone | 11.5% |
| Placebo | 3.0% |
Sources: the REDEFINE 1 publication and the American Diabetes Association’s trial presentation summary. These are group averages, not a promise of an individual’s result.
What does “each contributes” mean?
The trial’s reported difference was 5.5 percentage points more weight loss with the combination than semaglutide alone, and 8.9 points more than cagrilintide alone, under that analysis.
Those comparisons show an additional average benefit from the combination at the studied regimens in this population. They do not mean you can add the two individual percentages together. They also do not, by themselves, establish statistical “synergy” or tell us how every individual will respond.
What did REIMAGINE 2 find in people with type 2 diabetes?
REIMAGINE 2 studied a different population: 2,713 randomized adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor. Its primary comparison was CagriSema 2.4 mg/2.4 mg versus semaglutide 2.4 mg for HbA1c change at week 68. The trial also included cagrilintide-alone and placebo groups.
| Outcome | CagriSema 2.4/2.4 mg | Semaglutide 2.4 mg |
|---|---|---|
| HbA1c reduction | 1.91 percentage points | 1.75 percentage points |
| Body-weight loss | 14.2% | 10.2% |
The published REIMAGINE 2 paper reports the primary HbA1c comparison as a 0.16-percentage-point greater reduction with the combination (95% confidence interval 0.05 to 0.27 points). The sponsor announcement supplies the weight figures shown above and rounds the semaglutide HbA1c reduction to 1.76 points. The table uses the paper’s 1.75. Different participants and outcomes mean REIMAGINE 2 percentages should not be treated as a repeat of REDEFINE 1.
How was CagriSema given in these trials?
The studied CagriSema product was given by once-weekly injection under the skin. The milligram amounts above identify trial groups; they are not directions for an unrelated research vial. The November 2026 sponsor update describes the product and its investigational status.
Why do some headlines say 22.7%?
The sponsor reports 22.7% for CagriSema under a different analysis. The December 2025 filing announcement gives both figures.
- Treatment-policy: estimates the effect regardless of treatment discontinuation or rescue intervention.
- Trial-product: estimates the effect if participants used the study product as intended, including allowed trial doses.
These are different questions, called estimands. The second is not simply a rule to delete everyone who stopped, and it does not mean every participant took the maximum dose. The paper’s methods define the two questions; ICH’s guidance explains why defining the question matters.
What about side effects and approval?
Digestive effects were frequent: gastrointestinal adverse events were reported in 79.6% of the combination group versus 39.9% with placebo. A stronger average weight-loss result does not settle the benefit–risk decision for a person.
Approval check: November 20, 2026. Novo Nordisk’s November 15 update describes CagriSema as investigational and not approved in the United States. The trials tested controlled study products; they do not validate a separately sold blend or provide instructions for mixing ingredients.
Keep exploring
Start with cagrilintide versus CagriSema: the names explained, open the cagrilintide compound profile, or read reported reactions and their evidence. Read the REDEFINE 9 lower-dose results guide and the REDEFINE 4 versus REIMAGINE 5 comparison for separate trial questions. Our research-use-only guide explains how online research products differ from medicines and trial products.